Join
Live feed
·
PRReleasevia Quantisnow
Ventyx Biosciences Inc. logo

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024

ByQuantisnow·Wall Street's wire, on your screen.
VTYX· Ventyx Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VTYX (Ventyx Biosciences Inc.) and more on Quantisnow.